- Preparation and plant growth-regulatory activity of N'-substituted N- furfuryloxamides
-
N'-Substituted N-furfuryloxamides (4) were prepared via condensation of potassium methyl oxalate (8) with furfurylamine (5f) using 1,1'- oxalyldiimidazole (6), followed by hydrolysis of the resulting amide-ester (10), and finally condensation with aliphatic or aromatic amines (5). The prepared compounds (4) were examined for activity as plant growth regulators using two kinds of plant seeds, namely, those of rape, Brassica campestris L. (Dicotyledoneae) and leek, Allium tuberosum ROTTLER (Monocotyledoneae). N'- Benzyl- and N'-phenyl-N-furfuryloxamides (4b and 4c) and N,N'- difurfuryloxamide (4f) inhibited root growth in seedlings of both species.
- Kitagawa, Tokujiro,Tsutsui, Chinatsu,Hayashi, Kumi,Yamano, Aiko
-
-
Read Online
- Preparation method and application of D-dencichine
-
The invention discloses a preparation method and application of D-dencichine. The preparation method comprises the following steps: carrying out Fmoc protection on the amino group of D-asparagine so as to obtain a first intermediate; subjecting the first intermediate to Hoffman degradation reaction so as to obtain a second intermediate; subjecting the second intermediate to removal of Fmoc protection under the action of organic base so as to obtain a third intermediate; and subjecting the third intermediate and monomethyl oxalate to condensation reaction under a highly basic condition so as to obtain D-dencichine. D-dencichine is prepared by using the high-efficiency safe preparation method; the preparation method is simple and has high yield; the compound D-dencichine prepared by using the method has good treatment effect on thrombocytopenia and the effect is better than the effect of a clinical medicine interleukin-11, so D-dencichine can be used as a candidate medicine for treating thrombocytopenia.
- -
-
Paragraph 0051
(2016/10/17)
-
- METHODS OF NAD+-DEPENDENT DEACETYLASE INHIBITORS
-
The present invention relates to methods of treating cancer, cardiovascular disorders, and neurological disorders using NAD+-dependent deacetylase inhibitors.
- -
-
Page/Page column 25-26
(2008/06/13)
-